<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0182562</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-00785</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene identification and analysis</subject><subj-group><subject>Mutation detection</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Colorectal cancer</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Gastrointestinal tumors</subject><subj-group><subject>Pancreatic cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Lung and intrathoracic tumors</subject><subj-group><subject>Non-small cell lung cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Mutation</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>The prognostic value of <italic>KRAS</italic> mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis</article-title>
<alt-title alt-title-type="running-head">Prognostic <italic>KRAS</italic> from cfDNA in cancer patients</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Zhuang</surname>
<given-names>Rongyuan</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Song</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Qian</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Guo</surname>
<given-names>Xi</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Shen</surname>
<given-names>Feng</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Sun</surname>
<given-names>Hong</given-names>
</name>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8604-6311</contrib-id>
<name name-style="western">
<surname>Liu</surname>
<given-names>Tianshu</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Surgery, Affiliated Tumor Hospital of Anhui University of Science &amp; Technology (Huainan City Dongfang Tumor Hospital), Huainan, Anhui Province, China</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Galli</surname>
<given-names>Alvaro</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>CNR, ITALY</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">liutianshu1969@126.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>12</volume>
<issue>8</issue>
<elocation-id>e0182562</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>1</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>7</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>Zhuang et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0182562"/>
<abstract>
<p><italic>KRAS</italic> mutation has been found in various types of cancer. However, the prognostic value of <italic>KRAS</italic> mutation in cell-free DNA (cfDNA) in cancer patients was conflicting. In the present study, a meta-analysis was conducted to clarify its prognostic significance. Literature searches of Cochrane Library, EMBASE, PubMed and Web of Science were performed to identify studies related to <italic>KRAS</italic> mutation detected by cfDNA and survival in cancer patients. Two evaluators reviewed and extracted the information independently. Review Manager 5.3 software was used to perform the statistical analysis. Thirty studies were included in the present meta-analysis. Our analysis showed that <italic>KRAS</italic> mutation in cfDNA was associated with a poorer survival in cancer patients for overall survival (OS, HR 2.02, 95% CI 1.63–2.51, <italic>P</italic>&lt;0.01) and progression-free survival (PFS, HR 1.64, 95% CI 1.27–2.13, <italic>P</italic>&lt;0.01). In subgroup analyses, <italic>KRAS</italic> mutation in pancreatic cancer, colorectal cancer, non-small cell lung cancer and ovarian epithelial cancer had HRs of 2.81 (95% CI 1.83–4.30, <italic>P</italic>&lt;0.01), 1.67 (95% CI 1.25–2.42, <italic>P</italic>&lt;0.01), 1.64 (95% CI 1.13–2.39, <italic>P</italic> = 0.01) and 2.17 (95% 1.12–4.21, <italic>p</italic> = 0.02) for OS, respectively. In addition, the ethnicity didn’t influence the prognostic value of <italic>KRAS</italic> mutation in cfDNA in cancer patients (<italic>p</italic> = 0.39). Prognostic value of KRAS mutation was slightly higher in plasma than in serum (HR 2.13 vs 1.65), but no difference was observed (<italic>p</italic> = 0.37). Briefly, <italic>KRAS</italic> mutation in cfDNA was a survival prognostic biomarker in cancer patients. Its prognostic value was different in various types of cancer.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>Doctoral Fund of Ministry of Education of China</institution>
</funding-source>
<award-id>20130071110069</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Zhuang</surname>
<given-names>Rongyuan</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>The project was supported by Doctoral Fund of Ministry of Education of China (20130071110069).</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="2"/>
<page-count count="15"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>In recent years, the molecular biomarkers are increasingly being regarded as both predictive and prognostic tools for cancer patients. Currently, the alterations detection in biomarkers is considered the standard of care in many types of cancer, including lung, pancreatic, and colorectal cancer. For example, the National Comprehensive Cancer Network (NCCN) guidelines recommend testing for the <italic>KRAS</italic> alterations as a part of the initial diagnostic check for metastatic colorectal cancer (CRC) [<xref ref-type="bibr" rid="pone.0182562.ref001">1</xref>].</p>
<p><italic>KRAS</italic>, which is known as an important member of <italic>RAS</italic> family and encoded by the <italic>KRAS</italic> gene, is a small GTPase which cycles between active guanosine triphosphate (GTP)-bound (<italic>KRAS-</italic>GTP) and inactive guanosine diphosphate (GDP)-bound (<italic>KRAS</italic>-GDP) conformations. It plays a critical important role in normal tissue signaling. <italic>KRAS</italic> mutation can impair the intrinsic GTPase activity and lead to the permanent activation of its downstream signaling pathways, such as PI3K/AKT/mTOR and RAF/MEK/ERK [<xref ref-type="bibr" rid="pone.0182562.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0182562.ref003">3</xref>]. Several studies have reported that <italic>KRAS</italic> mutation could enhance the cellular proliferation, induce the malignant transformation [<xref ref-type="bibr" rid="pone.0182562.ref004">4</xref>–<xref ref-type="bibr" rid="pone.0182562.ref006">6</xref>]. As a result, the continuous activation would contribute to the development and maintenance in cancer.</p>
<p>A growing number of studies indicated that <italic>KRAS</italic> mutation was a prognostic biomarker to predict the survival outcomes in cancer patients. A previous meta-analysis had suggested that <italic>KRAS</italic> mutation was associated with a poorer overall survival in patients with pancreatic cancer, especially when the mutation detection was performed by the circulating tumor DNA [<xref ref-type="bibr" rid="pone.0182562.ref007">7</xref>]. However, the prognostic value of <italic>KRAS</italic> mutation detected by cfDNA on survival in other cancer patients is still not completely clear. Thus, in the present study, we conducted a meta-analysis to investigate the effect of <italic>KRAS</italic> mutation detected by cfDNA on survival in patients with cancer.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec003">
<title>Data sources and search strategy</title>
<p>The literature searches of EMBASE databases, Cochrane Library databases, and Web of Science were performed on June, 2016 and PubMed performed on March 2017. The main keywords used for the search were <italic>K-ras</italic> or <italic>KRAS</italic> or kirsten-ras or Kirsten ras or ki-ras, neoplasm or cancer or tumor or tumour or other subtypes/synonyms for cancer, liquid biopsy or serum or plasma or cell-free DNA or cell-free plasma DNA or cfDNA, and prognosis or survival. The detailed search terms and strategies were shown in <xref ref-type="supplementary-material" rid="pone.0182562.s001">S1 Table</xref>. Additionally, the full articles published were limited to English-language. The citation lists of retrieved articles were manually screened independently by two authors (ZYR and LS). All selected studies were checked according to a Newcastle-Ottawa Quality assessment Scale which was developed previously [<xref ref-type="bibr" rid="pone.0182562.ref008">8</xref>].</p>
</sec>
<sec id="sec004">
<title>Selection criteria</title>
<p>The inclusion criteria of our meta-analysis was as follows: (1) independently published observational study (case–control or cohort study) investigating the association between <italic>KRAS</italic> mutation detected by liquid biopsy and survival in cancer patients; (2) a study had reported the HR and its 95% CI for the association between <italic>KRAS</italic> mutation detected by cfDNA and survival in cancer patients; (3) a study had reported other indexes which could be used to calculate the HR and its 95% CI according to previously published methods[<xref ref-type="bibr" rid="pone.0182562.ref009">9</xref>,<xref ref-type="bibr" rid="pone.0182562.ref010">10</xref>]. In addition, the following exclusion criteria were also used: (1) abstracts and reviews; (2) studies without enough information; and (3) repeated or overlapping publications.</p>
</sec>
<sec id="sec005">
<title>Data extraction and quality assessment</title>
<p>The data extraction and quality assessment were performed by two investigators independently. The detailed information (first author, year of publication, period of study, the age of study population, country of study, ethnicity, cancer types and HR estimates) of each eligible study was collected. If several publications were overlapped, we selected the most recently published study or study with the largest numbers of subjects to be further analyzed. In addition, the discrepancies were reviewed and resolved in the present a third author (mainly SH).</p>
<p>The nine-star Newcastle–Ottawa Scale (NOS) was performed to assess the quality of each eligible study. With a NOS score equal or greater than seven, a study would be considered to be with high quality. An investigator would examine and adjudicate the information independently after data extraction and assessment.</p>
</sec>
<sec id="sec006">
<title>Statistical analysis</title>
<p>The HR and its related 95% CI reported or obtained by calculating in each study were performed to estimate the association between <italic>KRAS</italic> mutation in cfDNA and survival in cancer patients. If there was no heterogeneity existed, the fixed effects model was choose to assess the pooled HRs and its related 95%CIs; otherwise, the random effects model would be selected. The <italic>Chi</italic><sup><italic>2</italic></sup> and <italic>I</italic><sup><italic>2</italic></sup> statistic was used to assess and present the heterogeneity between the eligible studies. The funnel plot and Egger’s test were performed to assess the potential publication bias [<xref ref-type="bibr" rid="pone.0182562.ref011">11</xref>,<xref ref-type="bibr" rid="pone.0182562.ref012">12</xref>]. We considered that no publication bias existed, if the shape of the funnel plot was symmetrical and the <italic>P</italic> value of the Egger’s test was more than 0.05. In addition, a HR&lt;1 indicated <italic>KRAS</italic> mutation was associated with a better outcome while HR&gt;1 indicated <italic>KRAS</italic> mutation was associated with a worse outcome. <italic>P</italic> values were two sided and less than 0.05 were considered statistically different. The meta-analysis was performed through the Review Manager 5.3 software (Cochrane Collaboration).</p>
</sec>
</sec>
<sec id="sec007" sec-type="results">
<title>Results</title>
<sec id="sec008">
<title>Literature search and study selection</title>
<p>The literature searches resulted in 2391 studies at first. Then, 2343 records were excluded because of the duplications or no information on <italic>KRAS</italic> mutation detected by cfDNA and survival in cancer patients through the screening of the titles and abstracts of all studies. The rest of 46 records were screened by full texts. At last, there were 30 studies included in our meta-analysis [<xref ref-type="bibr" rid="pone.0182562.ref013">13</xref>–<xref ref-type="bibr" rid="pone.0182562.ref043">43</xref>]. The selection process for the eligible studies was shown in <xref ref-type="fig" rid="pone.0182562.g001">Fig 1</xref>.The main characteristics of the eligible studies were summarized in <xref ref-type="table" rid="pone.0182562.t001">Table 1</xref>. In addition, quality assessment of the eligible studies was shown in <xref ref-type="supplementary-material" rid="pone.0182562.s001">S1 Table</xref>.</p>
<fig id="pone.0182562.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182562.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow chart of selection process for the eligible studies.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182562.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0182562.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182562.t001</object-id>
<label>Table 1</label> <caption><title>The main characteristic of the studies included in the meta-analysis.</title></caption>
<alternatives>
<graphic id="pone.0182562.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182562.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"><sup>Study</sup></th>
<th align="left"><sup>Country</sup></th>
<th align="left"><sup>Study Period</sup></th>
<th align="left"><sup>Age (years)</sup></th>
<th align="left"><sup>Tumor Types</sup></th>
<th align="center"><sup>Stage</sup></th>
<th align="center"><sup>KRAS mutation/Total</sup></th>
<th align="center"><sup>Detection methods</sup></th>
<th align="center"><sup>Outcomes</sup></th>
<th align="center"><sup>HR estimates</sup></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><sup>Camps,2005[</sup><xref ref-type="bibr" rid="pone.0182562.ref014"><sup>14</sup></xref><sup>]</sup></td>
<td align="left"><sup>Spain</sup></td>
<td align="left"><sup>1999–2002</sup></td>
<td align="left"><sup>Median 64</sup></td>
<td align="left"><sup>Non-small cell lung cancer</sup></td>
<td align="left"><sup>IIIB-IV</sup></td>
<td align="center"><sup>20/67</sup></td>
<td align="left"><sup>Serum PCR-RFLP</sup></td>
<td align="left"><sup>OS, PFS</sup></td>
<td align="left"><sup>OS-KM</sup></td>
</tr>
<tr>
<td align="left"><sup>Camps,2011[</sup><xref ref-type="bibr" rid="pone.0182562.ref013"><sup>13</sup></xref><sup>]</sup></td>
<td align="left"><sup>Spain</sup></td>
<td align="left"><sup>NA</sup></td>
<td align="left"><sup>Median 60</sup></td>
<td align="left"><sup>Non-small cell lung cancer</sup></td>
<td align="left"><sup>IIIB-IV</sup></td>
<td align="center"><sup>27/251</sup></td>
<td align="left"><sup>Plasma Allelic Discrimination with RT-PCR</sup></td>
<td align="left"><sup>OS, PFS</sup></td>
<td align="left"><sup>KM</sup></td>
</tr>
<tr>
<td align="left"><sup>Castells,1999[</sup><xref ref-type="bibr" rid="pone.0182562.ref015"><sup>15</sup></xref><sup>]</sup></td>
<td align="left"><sup>Spain</sup></td>
<td align="left"><sup>1996–1997</sup></td>
<td align="left"><sup>Mean 62.6</sup></td>
<td align="left"><sup>Pancreatic cancer</sup></td>
<td align="left"><sup>I–IV</sup></td>
<td align="center"><sup>12/44</sup></td>
<td align="left"><sup>Plasma RELP-PCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>KM</sup></td>
</tr>
<tr>
<td align="left"><sup>Chen,2010[</sup><xref ref-type="bibr" rid="pone.0182562.ref016"><sup>16</sup></xref><sup>]</sup></td>
<td align="left"><sup>China</sup></td>
<td align="left"><sup>2007–2008</sup></td>
<td align="left"><sup>Median 60</sup></td>
<td align="left"><sup>Pancreatic cancer</sup></td>
<td align="left"><sup>Ⅲ–IV</sup></td>
<td align="center"><sup>30/91</sup></td>
<td align="left"><sup>Plasma Sequence</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>HR+CI (m)</sup></td>
</tr>
<tr>
<td align="left"><sup>Dobrzycka,2011[</sup><xref ref-type="bibr" rid="pone.0182562.ref017"><sup>17</sup></xref><sup>]</sup></td>
<td align="left"><sup>Poland</sup></td>
<td align="left"><sup>2002–2005</sup></td>
<td align="left"><sup>Median 58.3</sup></td>
<td align="left"><sup>Ovarian epithelial cancer</sup></td>
<td align="left"><sup>I–IV</sup></td>
<td align="center"><sup>27/126</sup></td>
<td align="left"><sup>Plasma PCR-RFLP</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>KM</sup></td>
</tr>
<tr>
<td align="left"><sup>Earl,2015[</sup><xref ref-type="bibr" rid="pone.0182562.ref018"><sup>18</sup></xref><sup>]</sup></td>
<td align="left"><sup>Spain</sup></td>
<td align="left"><sup>2009–2014</sup></td>
<td align="left"><sup>Median 68</sup></td>
<td align="left"><sup>Pancreatic cancer</sup></td>
<td align="left"><sup>LA, IV</sup></td>
<td align="center"><sup>8/31</sup></td>
<td align="left"><sup>Plasma ddPCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>HR+P</sup></td>
</tr>
<tr>
<td align="left"><sup>El Messaoudi, 2016[</sup><xref ref-type="bibr" rid="pone.0182562.ref019"><sup>19</sup></xref><sup>]</sup></td>
<td align="left"><sup>France</sup></td>
<td align="left"><sup>2010–2012</sup></td>
<td align="left"><sup>Median 66.6</sup></td>
<td align="left"><sup>Colorectal Cancer</sup></td>
<td align="left"><sup>IV</sup></td>
<td align="center"><sup>38/91</sup></td>
<td align="left"><sup>Plasma AS-PCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>HR+CI</sup></td>
</tr>
<tr>
<td align="left"><sup>Gautschi,2007[</sup><xref ref-type="bibr" rid="pone.0182562.ref020"><sup>20</sup></xref><sup>]</sup></td>
<td align="left"><sup>Switzerland</sup></td>
<td align="left"><sup>2001–2003</sup></td>
<td align="left"><sup>Median 61</sup></td>
<td align="left"><sup>Lung cancer</sup></td>
<td align="left"><sup>I–IV</sup></td>
<td align="center"><sup>16/175</sup></td>
<td align="left"><sup>Plasma PCR-RFLP</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>HR+CI</sup></td>
</tr>
<tr>
<td align="left"><sup>Hadano,2016[</sup><xref ref-type="bibr" rid="pone.0182562.ref021"><sup>21</sup></xref><sup>]</sup></td>
<td align="left"><sup>Japan</sup></td>
<td align="left"><sup>2007–2013</sup></td>
<td align="left"><sup>Median 69</sup></td>
<td align="left"><sup>Pancreatic cancer</sup></td>
<td align="left"><sup>I–IV</sup></td>
<td align="center"><sup>86/105</sup></td>
<td align="left"><sup>Plasma ddPCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>KM</sup></td>
</tr>
<tr>
<td align="left"><sup>Han,2016[</sup><xref ref-type="bibr" rid="pone.0182562.ref022"><sup>22</sup></xref><sup>]</sup></td>
<td align="left"><sup>Korea</sup></td>
<td align="left"><sup>NA</sup></td>
<td align="left"><sup>Median 58</sup></td>
<td align="left"><sup>non-small cell lung cancer</sup></td>
<td align="left"><sup>IIIB- IV</sup></td>
<td align="center"><sup>19/135 (OS) 7/59 (PFS)</sup></td>
<td align="left"><sup>Plasma PNA-PCR</sup></td>
<td align="left"><sup>OS, PFS</sup></td>
<td align="left"><sup>KM</sup></td>
</tr>
<tr>
<td align="left"><sup>Hara,2017[</sup><xref ref-type="bibr" rid="pone.0182562.ref023"><sup>23</sup></xref><sup>]</sup></td>
<td align="left"><sup>Japan</sup></td>
<td align="left"><sup>2010–2013</sup></td>
<td align="left"><sup>Median 67</sup></td>
<td align="left"><sup>colorectal cancer</sup></td>
<td align="left"><sup>I-III</sup></td>
<td align="center"><sup>26/71</sup></td>
<td align="left"><sup>Plasma NA</sup></td>
<td align="left"><sup>OS, PFS</sup></td>
<td align="left"><sup>OS-KM</sup><break/><sup>PFS-HR+CI(m)</sup></td>
</tr>
<tr>
<td align="left"><sup>Janowski,2017[</sup><xref ref-type="bibr" rid="pone.0182562.ref024"><sup>24</sup></xref><sup>]</sup></td>
<td align="left"><sup>United States</sup></td>
<td align="left"><sup>2011–2015</sup></td>
<td align="left"><sup>Median 56</sup></td>
<td align="left"><sup>colorectal cancer</sup></td>
<td align="left"><sup>IV</sup></td>
<td align="center"><sup>27/49</sup></td>
<td align="left"><sup>Plasma qPCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>HR+CI(m)</sup></td>
</tr>
<tr>
<td align="left"><sup>Kim,2015[</sup><xref ref-type="bibr" rid="pone.0182562.ref025"><sup>25</sup></xref><sup>]</sup></td>
<td align="left"><sup>Korea</sup></td>
<td align="left"><sup>2008–2011</sup></td>
<td align="left"><sup>Median 62</sup></td>
<td align="left"><sup>Colorectal Cancer</sup></td>
<td align="left"><sup>Advanced</sup></td>
<td align="center"><sup>26/65</sup></td>
<td align="left"><sup>Serum RFLP-PCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>KM</sup></td>
</tr>
<tr>
<td align="left"><sup>Kimura,2004[</sup><xref ref-type="bibr" rid="pone.0182562.ref026"><sup>26</sup></xref><sup>]</sup></td>
<td align="left"><sup>United States</sup></td>
<td align="left"><sup>2000–2002</sup></td>
<td align="left"><sup>Median 63</sup></td>
<td align="left"><sup>Non–Small-Cell Lung Cancer</sup></td>
<td align="left"><sup>IIIB-IV</sup></td>
<td align="center"><sup>5/25</sup></td>
<td align="left"><sup>Plasma RFLP-PCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>KM</sup></td>
</tr>
<tr>
<td align="left"><sup>Kingham,2016[</sup><xref ref-type="bibr" rid="pone.0182562.ref030"><sup>30</sup></xref><sup>]</sup></td>
<td align="left"><sup>United States</sup></td>
<td align="left"><sup>1990 to 2014</sup></td>
<td align="left"><sup>Age 59</sup></td>
<td align="left"><sup>Colorectal Cancer</sup></td>
<td align="left"><sup>I–IV</sup></td>
<td align="center"><sup>15/43</sup></td>
<td align="left"><sup>Serum qRT-PCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>Survival rate</sup></td>
</tr>
<tr>
<td align="left"><sup>Kinugasa,2015[</sup><xref ref-type="bibr" rid="pone.0182562.ref027"><sup>27</sup></xref><sup>]</sup></td>
<td align="left"><sup>Japan</sup></td>
<td align="left"><sup>2008–2010,</sup><break/><sup>2011–2013</sup></td>
<td align="left"><sup>Median 66</sup></td>
<td align="left"><sup>Pancreatic cancer</sup></td>
<td align="left"><sup>I–IV</sup></td>
<td align="center"><sup>101/141</sup></td>
<td align="left"><sup>Serum ddPCR-PHFA</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>HR+CI</sup></td>
</tr>
<tr>
<td align="left"><sup>Laethem,2017[</sup><xref ref-type="bibr" rid="pone.0182562.ref040"><sup>40</sup></xref><sup>]</sup></td>
<td align="left"><sup>German</sup></td>
<td align="left"><sup>NA</sup></td>
<td align="left"><sup>Median 63</sup></td>
<td align="left"><sup>Pancreatic cancer</sup></td>
<td align="left"><sup>II-IV</sup></td>
<td align="center"><sup>39/60</sup></td>
<td align="left"><sup>Plasma BEAMing</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>HR+CI</sup></td>
</tr>
<tr>
<td align="left"><sup>Nygaard,2013[</sup><xref ref-type="bibr" rid="pone.0182562.ref028"><sup>28</sup></xref><sup>]</sup></td>
<td align="left"><sup>Denmark</sup></td>
<td align="left"><sup>2007–2010</sup></td>
<td align="left"><sup>Median 66</sup></td>
<td align="left"><sup>Non-small cell lung cancer</sup></td>
<td align="left"><sup>Ⅱ-IV</sup></td>
<td align="center"><sup>43/246</sup></td>
<td align="left"><sup>Plasma ARMS-qPCR</sup></td>
<td align="left"><sup>OS, PFS</sup></td>
<td align="left"><sup>HR+CI(m)</sup></td>
</tr>
<tr>
<td align="left"><sup>Nygaard,2014[</sup><xref ref-type="bibr" rid="pone.0182562.ref029"><sup>29</sup></xref><sup>]</sup></td>
<td align="left"><sup>Denmark</sup></td>
<td align="left"><sup>NA</sup></td>
<td align="left"><sup>Median 64</sup></td>
<td align="left"><sup>Non-small cell lung cancer</sup></td>
<td align="left"><sup>III-IV</sup></td>
<td align="center"><sup>7/58</sup></td>
<td align="left"><sup>Plasma ARMS-qPCR</sup></td>
<td align="left"><sup>OS, PFS</sup></td>
<td align="left"><sup>HR+CI</sup></td>
</tr>
<tr>
<td align="left"><sup>Ramirez,2003[</sup><xref ref-type="bibr" rid="pone.0182562.ref031"><sup>31</sup></xref><sup>]</sup></td>
<td align="left"><sup>Spain</sup></td>
<td align="left"><sup>1998–1999</sup></td>
<td align="left"><sup>Median 62</sup></td>
<td align="left"><sup>Non-small cell lung cancer</sup></td>
<td align="left"><sup>I–IV</sup></td>
<td align="center"><sup>9/50</sup></td>
<td align="left"><sup>Serum RFLP-PCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>KM</sup></td>
</tr>
<tr>
<td align="left"><sup>Semrad,2015[</sup><xref ref-type="bibr" rid="pone.0182562.ref032"><sup>32</sup></xref><sup>]</sup></td>
<td align="left"><sup>United States</sup></td>
<td align="left"><sup>2009–2012</sup></td>
<td align="left"><sup>Median 67</sup></td>
<td align="left"><sup>Pancreatic cancer</sup></td>
<td align="left"><sup>Advanced or IV</sup></td>
<td align="center"><sup>10/27</sup></td>
<td align="left"><sup>Plasma ARMS</sup></td>
<td align="left"><sup>OS, PFS</sup></td>
<td align="left"><sup>KM</sup></td>
</tr>
<tr>
<td align="left"><sup>Singh,2015[</sup><xref ref-type="bibr" rid="pone.0182562.ref033"><sup>33</sup></xref><sup>]</sup></td>
<td align="left"><sup>India</sup></td>
<td align="left"><sup>2007–2011</sup></td>
<td align="left"><sup>Mean 55</sup></td>
<td align="left"><sup>Pancreatic cancer</sup></td>
<td align="left"><sup>42% of IV</sup></td>
<td align="center"><sup>34/110</sup></td>
<td align="left"><sup>Plasma RFLP-PCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>HR+CI</sup></td>
</tr>
<tr>
<td align="left"><sup>Spindler,2014[</sup><xref ref-type="bibr" rid="pone.0182562.ref036"><sup>36</sup></xref><sup>]</sup></td>
<td align="left"><sup>Denmark</sup></td>
<td align="left"><sup>2010–2012</sup></td>
<td align="left"><sup>Median 62</sup></td>
<td align="left"><sup>Colorectal Cancer</sup></td>
<td align="left"><sup>IV</sup></td>
<td align="center"><sup>29/86</sup></td>
<td align="left"><sup>Plasma ARMS-qPCR</sup></td>
<td align="left"><sup>OS, PFS</sup></td>
<td align="left"><sup>HR+CI(m)</sup></td>
</tr>
<tr>
<td align="left"><sup>Spindler,2015[</sup><xref ref-type="bibr" rid="pone.0182562.ref035"><sup>35</sup></xref><sup>]</sup></td>
<td align="left"><sup>Denmark</sup></td>
<td align="left"><sup>2010–2013</sup></td>
<td align="left"><sup>Median 63</sup></td>
<td align="left"><sup>Colorectal Cancer</sup></td>
<td align="left"><sup>IV</sup></td>
<td align="center"><sup>30/140</sup></td>
<td align="left"><sup>Plasma AS-PCR</sup></td>
<td align="left"><sup>OS, PFS</sup></td>
<td align="left"><sup>HR+CI (m)</sup></td>
</tr>
<tr>
<td align="left"><sup>Tabernero,2015[</sup><xref ref-type="bibr" rid="pone.0182562.ref037"><sup>37</sup></xref><sup>]</sup></td>
<td align="left"><sup>Spain</sup></td>
<td align="left"><sup>2010–2011</sup></td>
<td align="left"><sup>Median 61</sup></td>
<td align="left"><sup>Colorectal Cancer</sup></td>
<td align="left"><sup>IV</sup></td>
<td align="center"><sup>349/503</sup></td>
<td align="left"><sup>Plasma BEAMing</sup></td>
<td align="left"><sup>OS, PFS</sup></td>
<td align="left"><sup>HR+P</sup></td>
</tr>
<tr>
<td align="left"><sup>Takai,2015[</sup><xref ref-type="bibr" rid="pone.0182562.ref038"><sup>38</sup></xref><sup>]</sup></td>
<td align="left"><sup>Japan</sup></td>
<td align="left"><sup>2011–2014</sup></td>
<td align="left"><sup>Median 66</sup></td>
<td align="left"><sup>Pancreatic cancer</sup></td>
<td align="left"><sup>I–IV</sup></td>
<td align="center"><sup>83/259</sup></td>
<td align="left"><sup>Plasma ddPCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>HR+CI (m)</sup></td>
</tr>
<tr>
<td align="left"><sup>Tjensvoll,2016[</sup><xref ref-type="bibr" rid="pone.0182562.ref039"><sup>39</sup></xref><sup>]</sup></td>
<td align="left"><sup>Norway</sup></td>
<td align="left"><sup>2012–2014</sup></td>
<td align="left"><sup>Median 64</sup></td>
<td align="left"><sup>Pancreatic cancer</sup></td>
<td align="left"><sup>Advanced</sup></td>
<td align="center"><sup>10/14</sup></td>
<td align="left"><sup>Plasma ddPCR</sup></td>
<td align="left"><sup>OS, PFS</sup></td>
<td align="left"><sup>HR+P</sup></td>
</tr>
<tr>
<td align="left"><sup>Wang,2010[</sup><xref ref-type="bibr" rid="pone.0182562.ref041"><sup>41</sup></xref><sup>]</sup></td>
<td align="left"><sup>China</sup></td>
<td align="left"><sup>2005–2008</sup></td>
<td align="left"><sup>&gt;60 (53.8%)</sup></td>
<td align="left"><sup>non-small cell lung cancer</sup></td>
<td align="left"><sup>IIIB or stage IV</sup></td>
<td align="center"><sup>35/273</sup></td>
<td align="left"><sup>Plasma RFLP-PCR</sup></td>
<td align="left"><sup>PFS</sup></td>
<td align="left"><sup>KM</sup></td>
</tr>
<tr>
<td align="left"><sup>Xu,2014[</sup><xref ref-type="bibr" rid="pone.0182562.ref042"><sup>42</sup></xref><sup>]</sup></td>
<td align="left"><sup>China</sup></td>
<td align="left"><sup>2007–2011</sup></td>
<td align="left"><sup>Median 56</sup></td>
<td align="left"><sup>Colorectal cancer</sup></td>
<td align="left"><sup>IV</sup></td>
<td align="center"><sup>76/242</sup></td>
<td align="left"><sup>Plasma PNA-PCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>HR+CI (m)</sup></td>
</tr>
<tr>
<td align="left"><sup>Yamada,1998[</sup><xref ref-type="bibr" rid="pone.0182562.ref043"><sup>43</sup></xref><sup>]</sup></td>
<td align="left"><sup>Japan</sup></td>
<td align="left"><sup>1994–1997</sup></td>
<td align="left"><sup>Mean 63.9</sup></td>
<td align="left"><sup>Pancreatic cancer</sup></td>
<td align="left"><sup>I–IV</sup></td>
<td align="center"><sup>11/15</sup></td>
<td align="left"><sup>Plasma MASA-PCR</sup></td>
<td align="left"><sup>OS</sup></td>
<td align="left"><sup>OS value</sup></td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>HR, hazard ratio; CI, confidential interval; KM, Kaplan–Meier curve; AS-PCR, Allele-specific real-time quantitative PCR; m, multivariate analysis; p, p value</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Among thirty included studies, 12 studies and 29 studies which reported the association of <italic>KRAS</italic> mutation detected by cfDNA with OS and PFS in cancer patients respectively. The cancer types of the eligible studies included pancreatic cancer, colorectal cancer, non-small cell lung cancer and ovarian epithelial cancer. Among 29 studies reporting OS, there were 10 studies focusing on Asian population and 19 studies on non-Asian population. Serum samples and plasma samples were used to detect <italic>KRAS</italic> mutation in 4 studies and 25 studies respectively.</p>
</sec>
<sec id="sec009">
<title>Qualitative assessment</title>
<p>The quality assessment of studies was shown in <xref ref-type="supplementary-material" rid="pone.0182562.s002">S2 Table</xref>. The scores of the eligible studies ranged from 6 to 8. The average NOS score of the eligible studies was 7.2 which indicating that most of the studies were with a high quality.</p>
</sec>
<sec id="sec010">
<title>Survival prognosis of <italic>KRAS</italic> mutation in cfDNA in cancer patients</title>
<p>The meta-analysis was performed to investigate the prognostic value of <italic>KRAS</italic> mutation detected by cfDNA on survival in cancer patients. Our analysis showed that <italic>KRAS</italic> mutation detected by cfDNA was associated with a poorer survival in cancer patients for OS and PFS (HR = 2.02, 95% CI 1.63–2.51, <italic>P</italic>&lt;0.01 and HR = 1.64, 95% CI 1.27–2.13, <italic>P</italic>&lt;0.01, respectively) (Figs <xref ref-type="fig" rid="pone.0182562.g002">2</xref> and <xref ref-type="fig" rid="pone.0182562.g003">3</xref>). In subgroup analyses, <italic>KRAS</italic> mutation detected by cfDNA in pancreatic cancer, colorectal cancer, non-small cell lung cancer and ovarian epithelial cancer had HRs of 2.81 (95% CI 1.83–4.30, <italic>P</italic>&lt;0.01), 1.67 (95% CI 1.25–2.42, <italic>P</italic>&lt;0.01), 1.64 (95% CI 1.13–2.39, <italic>P</italic> = 0.01) and 2.17 (95% 1.12–4.21, <italic>p</italic> = 0.02) (shown in <xref ref-type="fig" rid="pone.0182562.g004">Fig 4</xref>), respectively. Additionally, the ethnicity didn`t influence the prognostic value of <italic>KRAS</italic> mutation detected by cfDNA in cancer patients. <italic>KRAS</italic> mutation detected by cfDNA was a significant prognostic biomarker in cancer patients either in Asian (HR 1.81, 95% CI 1.29–2.53, <italic>P</italic>&lt;0.01) or others population (HR 2.21, 95% CI 1.63–2.51, <italic>P</italic>&lt;0.01) (<xref ref-type="fig" rid="pone.0182562.g005">Fig 5</xref>).</p>
<fig id="pone.0182562.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182562.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Forest plot for the association between <italic>KRAS</italic> mutation detected by cell-free DNA and overall survival in cancer patients.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182562.g002" xlink:type="simple"/>
</fig>
<fig id="pone.0182562.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182562.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Forest plot for the association between <italic>KRAS</italic> mutation detected by cell-free DNA and progression free survival in cancer patients.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182562.g003" xlink:type="simple"/>
</fig>
<fig id="pone.0182562.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182562.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Forest plot for the subgroup analysis of cancer types.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182562.g004" xlink:type="simple"/>
</fig>
<fig id="pone.0182562.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182562.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Forest plot for the subgroup analysis of ethnicity.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182562.g005" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec011">
<title>Sensitivity analysis</title>
<p>Sensitivity analyses were presented in <xref ref-type="table" rid="pone.0182562.t002">Table 2</xref>. Firstly, the sensitivity analysis was performed through removing one single study one by one from the overall pooled analysis. The results showed that there was no significant alteration of the pooled HRs after removing one single study in turn which indicating the results of our meta-analysis was relative stable (data not showed). Additionally, studies with reported HRs of OS tended to have higher HRs compared with studies with recomputed HRs using Parmar’s method (2.24 vs 1.76, <italic>p</italic> = 0.24) for all studies. There was no significant difference compared multivariate HRs with univariate HRs (2.53 vs 2.29, <italic>p</italic> = 0.74). For samples collection, no significant difference between serum samples and plasma samples was observed (HRs, 1.65 vs 2.13, <italic>p</italic> = 0.37).</p>
<table-wrap id="pone.0182562.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182562.t002</object-id>
<label>Table 2</label> <caption><title>The sensitivity analysis for the meta-analysis.</title></caption>
<alternatives>
<graphic id="pone.0182562.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182562.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Subgroup</th>
<th align="center">HR (95%CI)</th>
<th align="center"><italic>p</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center"><bold>Type of publication</bold></td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">Reported</td>
<td align="center">2.24 (1.66–3.01)</td>
<td align="center">0.27</td>
</tr>
<tr>
<td align="center">Recalculated<break/>(by Parmar’s method)</td>
<td align="center">1.76 (1.30–2.40)</td>
<td align="center"/>
</tr>
<tr>
<td align="center"><bold>Analysis of hazard ratio</bold></td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">Multivariate</td>
<td align="center">2.53 (1.66–3.86)</td>
<td align="center">0.74</td>
</tr>
<tr>
<td align="center">Univariate</td>
<td align="center">2.29 (1.50–3.50)</td>
<td align="center"/>
</tr>
<tr>
<td align="center"><bold>Sample collection</bold></td>
<td align="center"/>
<td align="center"/>
</tr>
<tr>
<td align="center">Serum</td>
<td align="center">1.65 (0.99–2.74)</td>
<td align="center">0.37</td>
</tr>
<tr>
<td align="center">Plasma</td>
<td align="center">2.13 (1.69–2.70)</td>
<td align="center"/>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec012">
<title>Publication bias</title>
<p>The funnel plot and Egger’s test were used to assess the publication bias of the eligible studies. It seemed that the shape of the funnel plot was not symmetrical (shown in <xref ref-type="fig" rid="pone.0182562.g006">Fig 6A and 6B</xref>). In addition, the Egger’s test suggested that publication bias was existed (<italic>P</italic>&lt;0.05).</p>
<fig id="pone.0182562.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182562.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Funnel plot of the association between <italic>KRAS</italic> mutation detected by cell-free DNA and survival in cancer patients for publication bias.</title>
<p>a, overall survival; b, progression-free survival.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182562.g006" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec013" sec-type="conclusions">
<title>Discussion</title>
<p>Circulating cell-free DNA (cfDNA), which exists as small DNA fragments in blood, could be isolated from serum or plasma by less-invasive approach to diagnosis cancers, detect drug resistance and overcome the problem of tumor heterogeneity[<xref ref-type="bibr" rid="pone.0182562.ref044">44</xref>–<xref ref-type="bibr" rid="pone.0182562.ref046">46</xref>]. <italic>KRAS</italic> mutation is one of the most frequent molecular abnormalities found in several types of cancer such as pancreatic cancer, colorectal cancer, non-small cell lung cancer [<xref ref-type="bibr" rid="pone.0182562.ref047">47</xref>]. Spindler et al reported that there was strong relationship between the plasma levels of total cfDNA and the plasma <italic>KRAS</italic> mutated alleles in metastatic colorectal cancer [<xref ref-type="bibr" rid="pone.0182562.ref035">35</xref>]. Several studies found that cfDNA and the presence of mutant <italic>KRAS</italic> in plasma or serum cfDNA was significantly associated with the metastasis in patients with cancer [<xref ref-type="bibr" rid="pone.0182562.ref028">28</xref>,<xref ref-type="bibr" rid="pone.0182562.ref033">33</xref>,<xref ref-type="bibr" rid="pone.0182562.ref038">38</xref>,<xref ref-type="bibr" rid="pone.0182562.ref048">48</xref>]. In recent years, many studies found that <italic>KRAS</italic> mutation was associated with the recurrence [<xref ref-type="bibr" rid="pone.0182562.ref049">49</xref>–<xref ref-type="bibr" rid="pone.0182562.ref051">51</xref>] and with survival prognosis in various types of cancer [<xref ref-type="bibr" rid="pone.0182562.ref032">32</xref>,<xref ref-type="bibr" rid="pone.0182562.ref035">35</xref>][<xref ref-type="bibr" rid="pone.0182562.ref038">38</xref>], but several studies suggested that <italic>KRAS</italic> mutation in cfDNA was not associated with survival outcome of patients with pancreatic, lung or colon cancer [<xref ref-type="bibr" rid="pone.0182562.ref014">14</xref>,<xref ref-type="bibr" rid="pone.0182562.ref025">25</xref>,<xref ref-type="bibr" rid="pone.0182562.ref033">33</xref>]. The prognostic values of <italic>KRAS</italic> mutations in cfDNA as a biomarker remain to confirm. A meta-analysis had clarified that <italic>KRAS</italic> mutations in cfDNA had a more significant impact on overall survival of patients with pancreatic cancer compared with <italic>KRAS</italic> mutation detected in tumor tissue [<xref ref-type="bibr" rid="pone.0182562.ref007">7</xref>]. Our results indicated that <italic>KRAS</italic> detected in cfDNA was a prognostic marker for OS and PFS of pancreatic cancer, colorectal cancer and NSCLC. But another meta-analysis could not support <italic>KRAS</italic> mutation as survival marker in NSCLC [<xref ref-type="bibr" rid="pone.0182562.ref052">52</xref>]. One reason might be that more studies was included in our study (8 publications) compared with previous studies (4 publications). Maybe, large-scaled clinicltrials are necessary to confirm our results.</p>
<p>Currently, gene type analysis of tumor tissue is becoming a common practice in the clinical oncology, but there are some disadvantages such as tumor heterogeneity and samples being difficult to obtain. On the contrary, cfDNA is a non-invasive procedure and its samples would be easy to be collected [<xref ref-type="bibr" rid="pone.0182562.ref044">44</xref>,<xref ref-type="bibr" rid="pone.0182562.ref053">53</xref>]. Thus, considering the tumor heterogeneity of tumor tissue and the advantages of cfDNA, the cfDNA was selected according to the sample source in the present study. Furthermore, KRAS mutations in cfDNA is high correlated with mutations detected in the matched tumors [<xref ref-type="bibr" rid="pone.0182562.ref033">33</xref>,<xref ref-type="bibr" rid="pone.0182562.ref041">41</xref>]. Our meta-analysis showed that <italic>KRAS</italic> mutation detected in cfDNA was a significant prognostic biomarker of cancer patients, especially in pancreatic cancer.</p>
<p>Studies have suggested that the level of cfDNA is increased in both cancer patient and in various non-malignant pathological conditions compared to healthy individuals [<xref ref-type="bibr" rid="pone.0182562.ref048">48</xref>]. Even minority of healthy subjects demonstrated mutant KRAS in cfDNA [<xref ref-type="bibr" rid="pone.0182562.ref054">54</xref>], so the <italic>KRAS</italic> mutation used for disease diagnosis should be cautious. Generally, the prevalence of <italic>KRAS</italic> mutations in tumor tissues was high than that of cfDNA in pancreatic cancer and colorectal cancer [<xref ref-type="bibr" rid="pone.0182562.ref007">7</xref>,<xref ref-type="bibr" rid="pone.0182562.ref042">42</xref>]. Previous studies have suggested that the detection of tumor derived cfDNA is more trend in the setting of large tumor burden and tumor high turnover which are both independent predictors of a poor prognosis [<xref ref-type="bibr" rid="pone.0182562.ref038">38</xref>,<xref ref-type="bibr" rid="pone.0182562.ref048">48</xref>,<xref ref-type="bibr" rid="pone.0182562.ref055">55</xref>]. Result from Spindler et al [<xref ref-type="bibr" rid="pone.0182562.ref035">35</xref>] indicated there was strong relationship between the plasma levels of total cfDNA and the plasma <italic>KRAS</italic> mutated alleles in metastatic colorectal cancer. Several studies found that cfDNA and the presence of mutant <italic>KRAS</italic> in plasma or serum cfDNA was significantly associated with the metastasis in patients with cancer [<xref ref-type="bibr" rid="pone.0182562.ref028">28</xref>,<xref ref-type="bibr" rid="pone.0182562.ref033">33</xref>,<xref ref-type="bibr" rid="pone.0182562.ref038">38</xref>,<xref ref-type="bibr" rid="pone.0182562.ref048">48</xref>]. However, others reported there were no association observed between <italic>KRAS</italic> mutation and age, sex, tumor stage, histopathologic type and so on in advanced cancers [<xref ref-type="bibr" rid="pone.0182562.ref025">25</xref>,<xref ref-type="bibr" rid="pone.0182562.ref041">41</xref>]. In order to clarify this issue, we conducted a sensitivity analysis to compare univariate and multivariate analysis about prognostic value of <italic>KRAS</italic> in cfDNA in sensitivity analysis, and results proved <italic>KRAS</italic> mutation in cfDNA was an independent marker of poor prognosis of overall survival (HR = 2.53, 95%CI: 1.66–3.86, <italic>p</italic>&lt;0.01).</p>
<p>There were some limitations in the present meta-analysis. At first, most of the studies included in our meta-analysis were retrospective, which may bring about some potential bias. Second, some studies of other databases might be lost and some relevant studies were excluded in our meta-analysis because of the publication limitations or incompletely raw data. Third, several studies didn’t report HR and its related 95% CI and needed to be calculated according to Parmar’s method [<xref ref-type="bibr" rid="pone.0182562.ref009">9</xref>] which might cause imprecise values and potential bias. In addition, there was heterogeneity existed in the eligible studies which might lead to an inaccurate conclusion.</p>
<p>In conclusion, our meta-analysis demonstrated that <italic>KRAS</italic> mutation detected in cfDNA was a prognostic biomarker in cancer patients. Its prognostic value was different in different types of cancer. However, because of the limitations existed in our meta-analysis, more studies are still needed to support our conclusions.</p>
</sec>
<sec id="sec014">
<title>Supporting information</title>
<supplementary-material id="pone.0182562.s001" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0182562.s001" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>The search strategy of the prognostic value of <italic>KRAS</italic> mutation detected by cell-free DNA in cancer patients.</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0182562.s002" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0182562.s002" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Application of the quality assessment tool NOS to the studies included in the meta-analysis.</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0182562.s003" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0182562.s003" xlink:type="simple">
<label>S3 Table</label>
<caption>
<title>PRISMA 2009 checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>The project was supported by Doctoral Fund of Ministry of Education of China (20130071110069).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0182562.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Benson</surname> <given-names>AB, 3rd</given-names></name>, <name name-style="western"><surname>Venook</surname> <given-names>AP</given-names></name>, <name name-style="western"><surname>Cederquist</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>YJ</given-names></name>, <name name-style="western"><surname>Cooper</surname> <given-names>HS</given-names></name>, <etal>et al</etal>. <article-title>Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology</article-title>. <source>J Natl Compr Canc Netw</source>. <year>2017</year>; <volume>15</volume>: <fpage>370</fpage>–<lpage>398</lpage>. <object-id pub-id-type="pmid">28275037</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zeitouni</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Pylayeva-Gupta</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Der</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Bryant</surname> <given-names>KL</given-names></name>. <article-title>KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment</article-title>. <source>Cancers (Basel)</source>. <year>2016</year>; <volume>8</volume>: <fpage>E45</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/cancers8040045" xlink:type="simple">10.3390/cancers8040045</ext-link></comment> <object-id pub-id-type="pmid">27096871</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhou</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Der</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Cox</surname> <given-names>AD</given-names></name>. <article-title>The role of wild type RAS isoforms in cancer</article-title>. <source>Semin Cell Dev Biol</source>. <year>2016</year>; <volume>58</volume>: <fpage>60</fpage>–<lpage>69</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.semcdb.2016.07.012" xlink:type="simple">10.1016/j.semcdb.2016.07.012</ext-link></comment> <object-id pub-id-type="pmid">27422332</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qian</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Niu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Chiao</surname> <given-names>PJ</given-names></name>, <name name-style="western"><surname>Tsao</surname> <given-names>MS</given-names></name>. <article-title>In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis</article-title>. <source>Cancer Res</source>. <year>2005</year>; <volume>65</volume>: <fpage>5045</fpage>–<lpage>5053</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/0008-5472.CAN-04-3208" xlink:type="simple">10.1158/0008-5472.CAN-04-3208</ext-link></comment> <object-id pub-id-type="pmid">15958547</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brembeck</surname> <given-names>FH</given-names></name>, <name name-style="western"><surname>Schreiber</surname> <given-names>FS</given-names></name>, <name name-style="western"><surname>Deramaudt</surname> <given-names>TB</given-names></name>, <name name-style="western"><surname>Craig</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Rhoades</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Swain</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice</article-title>. <source>Cancer Res</source>. <year>2003</year>; <volume>63</volume>: <fpage>2005</fpage>–<lpage>2009</lpage>. <object-id pub-id-type="pmid">12727809</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Collins</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Bednar</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Brisset</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Galban</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Galban</surname> <given-names>CJ</given-names></name>, <etal>et al</etal>. <article-title>Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice</article-title>. <source>J Clin Invest</source>. <year>2012</year>; <volume>122</volume>: <fpage>639</fpage>–<lpage>653</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI59227" xlink:type="simple">10.1172/JCI59227</ext-link></comment> <object-id pub-id-type="pmid">22232209</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Zheng</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Zhuang</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis</article-title>. <source>Med Oncol</source>. <year>2016</year>; <volume>33</volume>: <fpage>61</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s12032-016-0777-1" xlink:type="simple">10.1007/s12032-016-0777-1</ext-link></comment> <object-id pub-id-type="pmid">27225938</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stang</surname> <given-names>A</given-names></name>. <article-title>Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses</article-title>. <source>Eur J Epidemiol</source>. <year>2010</year>; <volume>25</volume>: <fpage>603</fpage>–<lpage>605</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10654-010-9491-z" xlink:type="simple">10.1007/s10654-010-9491-z</ext-link></comment> <object-id pub-id-type="pmid">20652370</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parmar</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Torri</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Stewart</surname> <given-names>L</given-names></name>. <article-title>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</article-title>. <source>Stat Med</source>. <year>1998</year>; <volume>17</volume>: <fpage>2815</fpage>–<lpage>2834</lpage>. <object-id pub-id-type="pmid">9921604</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tierney</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Stewart</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Ghersi</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Burdett</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sydes</surname> <given-names>MR</given-names></name>. <article-title>Practical methods for incorporating summary time-to-event data into meta-analysis</article-title>. <source>Trials</source>. <year>2007</year>; <volume>8</volume>: <fpage>16</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1745-6215-8-16" xlink:type="simple">10.1186/1745-6215-8-16</ext-link></comment> <object-id pub-id-type="pmid">17555582</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>. <year>1994</year>; <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>Bmj</source>. <year>1997</year>; <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage>. <object-id pub-id-type="pmid">9310563</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Camps</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Jantus-Lewintre</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Cabrera</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Blasco</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Sanmartin</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Gallach</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients</article-title>. <source>Lung Cancer</source>. <year>2011</year>; <volume>72</volume>: <fpage>365</fpage>–<lpage>369</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.lungcan.2010.09.005" xlink:type="simple">10.1016/j.lungcan.2010.09.005</ext-link></comment> <object-id pub-id-type="pmid">21074889</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Camps</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Sirera</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Bremnes</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Blasco</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Sancho</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Bayo</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?</article-title> <source>Lung Cancer</source>. <year>2005</year>; <volume>50</volume>: <fpage>339</fpage>–<lpage>346</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.lungcan.2005.06.007" xlink:type="simple">10.1016/j.lungcan.2005.06.007</ext-link></comment> <object-id pub-id-type="pmid">16139926</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Castells</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Puig</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Mora</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Boadas</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Boix</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Urgell</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance</article-title>. <source>J Clin Oncol</source>. <year>1999</year>; <volume>17</volume>: <fpage>578</fpage>–<lpage>584</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.1999.17.2.578" xlink:type="simple">10.1200/JCO.1999.17.2.578</ext-link></comment> <object-id pub-id-type="pmid">10080602</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Tu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Meng</surname> <given-names>ZQ</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>LM</given-names></name>. <article-title>K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer</article-title>. <source>Eur J Surg Oncol</source>.<year>2010</year>; <volume>36</volume>: <fpage>657</fpage>–<lpage>662</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ejso.2010.05.014" xlink:type="simple">10.1016/j.ejso.2010.05.014</ext-link></comment> <object-id pub-id-type="pmid">20542658</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dobrzycka</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Terlikowski</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Kinalski</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kowalczuk</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Niklinska</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Chyczewski</surname> <given-names>L</given-names></name>. <article-title>Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers</article-title>. <source>Ann Oncol</source><year>2011</year>; <volume>22</volume>: <fpage>1133</fpage>–<lpage>1140</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/annonc/mdq584" xlink:type="simple">10.1093/annonc/mdq584</ext-link></comment> <object-id pub-id-type="pmid">21098618</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Earl</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Garcia-Nieto</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Martinez-Avila</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Montans</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Sanjuanbenito</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rodriguez-Garrote</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer</article-title>.<source>BMC Cancer</source>. <year>2015</year>; <volume>15</volume>: <fpage>797</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12885-015-1779-7" xlink:type="simple">10.1186/s12885-015-1779-7</ext-link></comment> <object-id pub-id-type="pmid">26498594</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>El Messaoudi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mouliere</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Du Manoir</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Bascoul-Mollevi</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gillet</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Nouaille</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care</article-title>. <source>Clin Cancer Res</source>. <year>2016</year>; <volume>22</volume>: <fpage>3067</fpage>–<lpage>3077</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/1078-0432.CCR-15-0297" xlink:type="simple">10.1158/1078-0432.CCR-15-0297</ext-link></comment> <object-id pub-id-type="pmid">26847055</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gautschi</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Huegli</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Ziegler</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gugger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Heighway</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ratschiller</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Origin and prognostic value of circulating KRAS mutations in lung cancer patients</article-title>. <source>Cancer Letter</source> <year>2007</year>; <volume>254</volume>: <fpage>265</fpage>–<lpage>273</lpage>.</mixed-citation></ref>
<ref id="pone.0182562.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hadano</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Murakami</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Uemura</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hashimoto</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kondo</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Nakagawa</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer</article-title>. <source>Br J Cancer</source>. <year>2016</year>; <volume>115</volume>: <fpage>59</fpage>–<lpage>65</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/bjc.2016.175" xlink:type="simple">10.1038/bjc.2016.175</ext-link></comment> <object-id pub-id-type="pmid">27280632</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Han</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Han</surname> <given-names>YL</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>GK</given-names></name>. <article-title>PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer</article-title>. <source>BMC Cancer</source>. <year>2016</year>; <volume>16</volume>: <fpage>627</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12885-016-2678-2" xlink:type="simple">10.1186/s12885-016-2678-2</ext-link></comment> <object-id pub-id-type="pmid">27519791</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hara</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nagasaki</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Shiga</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Takahashi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Takeyama</surname> <given-names>H</given-names></name>. <article-title>High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab</article-title>. <source>Surg Today</source>. <year>2017</year>; <volume>47</volume>: <fpage>483</fpage>–<lpage>489</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00595-016-1404-7" xlink:type="simple">10.1007/s00595-016-1404-7</ext-link></comment> <object-id pub-id-type="pmid">27549777</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Janowski</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Timofeeva</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Chasovskikh</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Goldberg</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Banovac</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies</article-title>. <source>Oncol Rep</source>. <year>2017</year>; <volume>37</volume>: <fpage>57</fpage>–<lpage>65</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3892/or.2016.5284" xlink:type="simple">10.3892/or.2016.5284</ext-link></comment> <object-id pub-id-type="pmid">28004119</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>ST</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Jin</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Sung</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Choi</surname> <given-names>YJ</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YH</given-names></name>. <article-title>Can serum be used for analyzing the KRAS mutation status in patients with advanced colorectal cancer?</article-title>. <source>Cancer Res Treat</source>. <year>2015</year>; <volume>47</volume>: <fpage>796</fpage>–<lpage>803</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4143/crt.2014.106" xlink:type="simple">10.4143/crt.2014.106</ext-link></comment> <object-id pub-id-type="pmid">25687873</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kimura</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Holland</surname> <given-names>WS</given-names></name>, <name name-style="western"><surname>Kawaguchi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Williamson</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Chansky</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Crowley</surname> <given-names>JJ</given-names></name>, <etal>et al</etal>. <article-title>Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy</article-title>. <source>Ann N Y Acad Sci</source>. <year>2004</year>; <volume>1022</volume>: <fpage>55</fpage>–<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1196/annals.1318.010" xlink:type="simple">10.1196/annals.1318.010</ext-link></comment> <object-id pub-id-type="pmid">15251940</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kinugasa</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Nouso</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Miyahara</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Morimoto</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Dohi</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Tsutsumi</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer</article-title>. <source>Cancer</source>. <year>2015</year>; <volume>121</volume>: <fpage>2271</fpage>–<lpage>2280</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/cncr.29364" xlink:type="simple">10.1002/cncr.29364</ext-link></comment> <object-id pub-id-type="pmid">25823825</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nygaard</surname> <given-names>AD</given-names></name>, <name name-style="western"><surname>Garm Spindler</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Pallisgaard</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Andersen</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Jakobsen</surname> <given-names>A</given-names></name>. <article-title>The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer</article-title>.<source>Oncol Rep</source>. <year>2013</year>; <volume>31</volume>: <fpage>312</fpage>–<lpage>317</lpage>.</mixed-citation></ref>
<ref id="pone.0182562.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nygaard</surname> <given-names>AD</given-names></name>, <name name-style="western"><surname>Spindler</surname> <given-names>KLG</given-names></name>, <name name-style="western"><surname>Pallisgaard</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Andersen</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Jakobsen</surname> <given-names>A</given-names></name>. <article-title>Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC</article-title>. <source>Oncol Rep</source>. <year>2014</year>; <volume>31</volume>: <fpage>969</fpage>–<lpage>974</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3892/or.2013.2906" xlink:type="simple">10.3892/or.2013.2906</ext-link></comment> <object-id pub-id-type="pmid">24316734</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kingham</surname> <given-names>TP</given-names></name>, <name name-style="western"><surname>Nguyen</surname> <given-names>HC</given-names></name>, <name name-style="western"><surname>Zheng</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Konstantinidis</surname> <given-names>IT</given-names></name>, <name name-style="western"><surname>Sadot</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Shia</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>MicroRNA-203 predicts human survival after resection of colorectal liver metastasis</article-title>. <source>Oncotarget</source>. <year>2016</year>; <volume>8</volume>: <fpage>18821</fpage>–<lpage>18831</lpage>.</mixed-citation></ref>
<ref id="pone.0182562.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ramirez</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Sarries</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>de Castro</surname> <given-names>PL</given-names></name>, <name name-style="western"><surname>Roig</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Queralt</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Escuin</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients</article-title>. <source>Cancer Lett</source>. <year>2003</year>; <volume>193</volume>: <fpage>207</fpage>–<lpage>216</lpage>. <object-id pub-id-type="pmid">12706879</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Semrad</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Barzi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lenz</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Hutchins</surname> <given-names>IM</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>EJ</given-names></name>, <name name-style="western"><surname>Gong</surname> <given-names>IY</given-names></name>, <etal>et al</etal>. <article-title>Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results</article-title>. <source>Int J Clin Oncol</source>. <year>2015</year>; <volume>20</volume>: <fpage>518</fpage>–<lpage>524</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10147-014-0730-2" xlink:type="simple">10.1007/s10147-014-0730-2</ext-link></comment> <object-id pub-id-type="pmid">25091263</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Singh</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Gupta</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pandey</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Chauhan</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Saraya</surname> <given-names>A</given-names></name>. <article-title>High levels of cell-free circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival</article-title>. <source>Cancer Invest</source>. <year>2015</year>; <volume>33</volume>: <fpage>78</fpage>–<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3109/07357907.2014.1001894" xlink:type="simple">10.3109/07357907.2014.1001894</ext-link></comment> <object-id pub-id-type="pmid">25647443</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spindler</surname> <given-names>KG</given-names></name>, <name name-style="western"><surname>Appelt</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Pallisgaard</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Andersen</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Jakobsen</surname> <given-names>A</given-names></name>. <article-title>KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer</article-title>. <source>Br J <bold>Cancer</bold></source>. <year>2013</year>; <volume>111</volume>: <fpage>3067</fpage>–<lpage>3072</lpage>.</mixed-citation></ref>
<ref id="pone.0182562.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spindler</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Pallisgaard</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Appelt</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Andersen</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Schou</surname> <given-names>JV</given-names></name>, <name name-style="western"><surname>Nielsen</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy</article-title>. <source>Eur J Cancer</source>.<year>2015</year>; <volume>51</volume>: <fpage>2678</fpage>–<lpage>2685</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ejca.2015.06.118" xlink:type="simple">10.1016/j.ejca.2015.06.118</ext-link></comment> <object-id pub-id-type="pmid">26508156</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spindler</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Pallisgaard</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Vogelius</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Jakobsen</surname> <given-names>A</given-names></name>. <article-title>Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan</article-title>. <source>Clin Cancer Res</source>. <year>2012</year>; <volume>18</volume>: <fpage>1177</fpage>–<lpage>1185</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/1078-0432.CCR-11-0564" xlink:type="simple">10.1158/1078-0432.CCR-11-0564</ext-link></comment> <object-id pub-id-type="pmid">22228631</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tabernero</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lenz</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Siena</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sobrero</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Falcone</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ychou</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: A retrospective, exploratory analysis of the CORRECT trial</article-title>. <source>Lancet Oncol</source>. <year>2015</year>; <volume>16</volume>: <fpage>937</fpage>–<lpage>948</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1470-2045(15)00138-2" xlink:type="simple">10.1016/S1470-2045(15)00138-2</ext-link></comment> <object-id pub-id-type="pmid">26184520</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Takai</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Totoki</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Nakamura</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Morizane</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Nara</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Hama</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer</article-title>. <source>Sci Rep</source>. <year>2015</year>; <volume>5</volume>: <fpage>18425</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep18425" xlink:type="simple">10.1038/srep18425</ext-link></comment> <object-id pub-id-type="pmid">26669280</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tjensvoll</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Lapin</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Buhl</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Oltedal</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Berry</surname> <given-names>KS-O</given-names></name>, <name name-style="western"><surname>Gilje</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer</article-title>. <source>Molecular Oncology</source>. <year>2016</year>; <volume>10</volume>: <fpage>635</fpage>–<lpage>643</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.molonc.2015.11.012" xlink:type="simple">10.1016/j.molonc.2015.11.012</ext-link></comment> <object-id pub-id-type="pmid">26725968</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Van Laethem</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Riess</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Jassem</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Haas</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Martens</surname> <given-names>UM</given-names></name>, <name name-style="western"><surname>Weekes</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Phase I/II Study of Refametinib (BAY 86–9766) in Combination with Gemcitabine in Advanced Pancreatic cancer</article-title>. <source>Target Oncol</source>. <year>2017</year>; <volume>12</volume>: <fpage>97</fpage>–<lpage>109</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11523-016-0469-y" xlink:type="simple">10.1007/s11523-016-0469-y</ext-link></comment> <object-id pub-id-type="pmid">27975152</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>An</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Zhuo</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer</article-title>. <source>Clin Cancer Res</source>. <year>2010</year>; <volume>16</volume>: <fpage>1324</fpage>–<lpage>1330</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/1078-0432.CCR-09-2672" xlink:type="simple">10.1158/1078-0432.CCR-09-2672</ext-link></comment> <object-id pub-id-type="pmid">20145159</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>XJ</given-names></name>, <name name-style="western"><surname>Ge</surname> <given-names>FJ</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Sharma</surname> <given-names>MR</given-names></name>, <etal>et al</etal>. <article-title>KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer</article-title>.<source>J Exp Clin Cancer Res</source>. <year>2014</year>; <volume>33</volume>: <fpage>104</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13046-014-0104-7" xlink:type="simple">10.1186/s13046-014-0104-7</ext-link></comment> <object-id pub-id-type="pmid">25491325</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yamada</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nakamori</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ohzato</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Oshima</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Aoki</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Higaki</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features</article-title>. <source>Clin Cancer Res</source>. <year>1998</year>; <volume>4</volume>: <fpage>1527</fpage>–<lpage>1532</lpage>. <object-id pub-id-type="pmid">9626473</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Diaz</surname> <given-names>LA</given-names> <suffix>Jr.</suffix></name>, <name name-style="western"><surname>Bardelli</surname> <given-names>A</given-names></name>. <article-title>Liquid biopsies: genotyping circulating tumor DNA</article-title>. <source>J Clin Oncol</source>. <year>2014</year>; <volume>32</volume>: <fpage>579</fpage>–<lpage>586</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2012.45.2011" xlink:type="simple">10.1200/JCO.2012.45.2011</ext-link></comment> <object-id pub-id-type="pmid">24449238</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Riediger</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Dietz</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Schirmer</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Meister</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Heinzmann-Groth</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients</article-title>. <source>Sci Rep</source>. <year>2016</year>; <volume>6</volume>: <fpage>33505</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep33505" xlink:type="simple">10.1038/srep33505</ext-link></comment> <object-id pub-id-type="pmid">27640882</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oxnard</surname> <given-names>GR</given-names></name>, <name name-style="western"><surname>Paweletz</surname> <given-names>CP</given-names></name>, <name name-style="western"><surname>Kuang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Mach</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>O'Connell</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Messineo</surname> <given-names>MM</given-names></name>, <etal>et al</etal>. <article-title>Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA</article-title>. <source>Clinical Cancer Research</source>. <year>2014</year>; <volume>20</volume>: <fpage>1698</fpage>–<lpage>1705</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/1078-0432.CCR-13-2482" xlink:type="simple">10.1158/1078-0432.CCR-13-2482</ext-link></comment> <object-id pub-id-type="pmid">24429876</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Prior</surname> <given-names>IA</given-names></name>, <name name-style="western"><surname>Lewis</surname> <given-names>PD</given-names></name>, <article-title>Mattos C A comprehensive survey of Ras mutations in cancer</article-title>. <source>Cancer Res</source>. <year>2012</year>; <volume>72</volume>: <fpage>2457</fpage>–<lpage>2467</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/0008-5472.CAN-11-2612" xlink:type="simple">10.1158/0008-5472.CAN-11-2612</ext-link></comment> <object-id pub-id-type="pmid">22589270</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spindler</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Appelt</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Pallisgaard</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Andersen</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Brandslund</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Jakobsen</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer</article-title>. <source>Int J Cancer</source>. <year>2014</year>; <volume>135</volume>: <fpage>2984</fpage>–<lpage>2991</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/ijc.28946" xlink:type="simple">10.1002/ijc.28946</ext-link></comment> <object-id pub-id-type="pmid">24798213</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref049"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Wang JSZ, Sausen M, Parpart-Li S, Murphy DM, Velculescu VE, Wood LD, et al. Circulating tumor DNA (ctDNA) as a prognostic marker for recurrence in resected pancreas cancer. 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. 15 SUPPL. 1.</mixed-citation></ref>
<ref id="pone.0182562.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Garcia-Murillas</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Schiavon</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Weigelt</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Ng</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hrebien</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Cutts</surname> <given-names>RJ</given-names></name>, <etal>et al</etal>. <article-title>Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer</article-title>. <source>Sci Transl Med</source>. <year>2015</year>; <volume>7</volume>: <fpage>302ra133</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/scitranslmed.aab0021" xlink:type="simple">10.1126/scitranslmed.aab0021</ext-link></comment> <object-id pub-id-type="pmid">26311728</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref051"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Lin SH, Xu T, He J, Banks K, Lanman RB, Sebisanovic D, et al. Dynamic changes in cell-free circulating tumor dna to track tumor response and risk of recurrence in stage III non-small cell lung cancer. 16th World Conference on Lung Cancer Denver, CO United States. 9 SUPPL. 2015; pp. S287.</mixed-citation></ref>
<ref id="pone.0182562.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ai</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Peng</surname> <given-names>P</given-names></name>. <article-title>Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer</article-title>. <source>Oncotarget</source>. <year>2016</year>; <volume>7</volume>: <fpage>44583</fpage>–<lpage>44595</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.10069" xlink:type="simple">10.18632/oncotarget.10069</ext-link></comment> <object-id pub-id-type="pmid">27323821</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hofman</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Popper</surname> <given-names>HH</given-names></name>. <article-title>Pathologists and liquid biopsies: to be or not to be?</article-title> <source>Virchows Arch</source>. <year>2016</year>; <volume>469</volume>: <fpage>601</fpage>–<lpage>609</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00428-016-2004-z" xlink:type="simple">10.1007/s00428-016-2004-z</ext-link></comment> <object-id pub-id-type="pmid">27553354</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Che</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>Kurywchak</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Tavormina</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Gansmo</surname> <given-names>LB</given-names></name>, <name name-style="western"><surname>Correa de Sampaio</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer</article-title>. <source>Cancer Biol Ther</source>. <year>2017</year>; <volume>18</volume>: <fpage>158</fpage>–<lpage>165</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/15384047.2017.1281499" xlink:type="simple">10.1080/15384047.2017.1281499</ext-link></comment> <object-id pub-id-type="pmid">28121262</object-id></mixed-citation></ref>
<ref id="pone.0182562.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pereira</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Camacho-Vanegas</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Anand</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sebra</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Catalina Camacho</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Garnar-Wortzel</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>: <fpage>e0145754</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0145754" xlink:type="simple">10.1371/journal.pone.0145754</ext-link></comment> <object-id pub-id-type="pmid">26717006</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>